#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Click here to read this study in NEJM.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Once-monthly bofanglutide maintained weight loss over 24 weeks in topline phase 3 results

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

Tags: obesity Orforglipron

#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Once-monthly bofanglutide maintained weight loss over 24 weeks in topline phase 3 results

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

#VisualAbstract: Pitavastatin reduces cardiovascular event risk among patients with HIV

CRISPR-Cas9 promoting fetal hemoglobin production improves severe sickle cell disease

RelatedReports

Once-monthly bofanglutide maintained weight loss over 24 weeks in topline phase 3 results

Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment

Orforglipron (Foundayo) expands oral treatment options for weight management

CRISPR-Cas9 promoting fetal hemoglobin production improves severe sickle cell disease

Video laryngoscopy leads to higher success on first intubation attempt than direct laryngoscopy

#VisualAbstract: Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure

2MM+ All Access

Recent Reports

Get the app

Keep reading with 2 Minute Medicine+

Keep reading with 2 Minute Medicine+

The medical literature, distilled daily.

Membership benefits